glp-1 receptor agonist use and risk of suicide death Cardiovascular mortality outcomes with agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia JAMA - Most viewed in
Description
Mounjaro is not currently approved for this indication
While these findings describe the average response, individual responses can vary widely, highlighting the complexity of obesity as a disease
What stood out to me is how were moving beyond traditional glucose control toward a more holistic metabolic approach
and Niazi S
